Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer ...

Meredith McKean, MD, discusses a longer-term follow-up study investigating fianlimab and cemiplimab immunotherapy in advanced ...

The novel ROS1 inhibitor zidesamtinib demonstrated promising early activity in heavily pretreated patients with advanced ROS1 ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

A statistically significant improvement in progression-free survival and objective response rate was seen with belzutifan ...

The study found that lenvatinib continued to demonstrate improved efficacy in patients with radioiodine-refractory ...

Ruxolitinib can cause cytopenia, the most prominent adverse event (AE). There are rates of anemia and thrombocytopenia in ...

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less ...

The phase 3 Shorespan-007 trial will compare bomedemstat with hydroxyurea in patients with treatment-naive essential ...

HER2DX has shown a strong association between ERBB2 mRNA and survival in patients with HER2-positive breast cancer.

The investigational new drug application for VNX-101, a gene therapy aimed at treating CD19-positive acute lymphoblastic ...

The next-generation radiopharmaceutical ABD-147 was previously granted FDA fast track designation in extensive-stage small ...